A Phase 3 interventional study of Leuprolide Acetate 3 Month Depot in Precocious, Leuprolide Acetate and Luteinizing Hormone (LH), sponsored by AbbVie (prior sponsor, Abbott). Completed at 20 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 3rd registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 2 started in 2008.
This study's enrollment of 72 is above the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
AbbVie has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
This study includes a 36-month Study Drug Treatment Period (3-month treatment cycles), and a Safety Follow-up Period (12 weeks following the Month 36 visit). Participants will receive a total of twelve injections of the same treatment they received in the lead-in study, L-CP07-167 (NCT00635817) either leuprolide acetate 11.25 mg or 30 mg depot formulation. Each injection will be administered 3 months apart for up to 36 months of treatment. Study visits will occur on Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 and 33 (1st through the 12th leuprolide acetate depot injections, respectively), Month 36, and 12 weeks later for the Safety Follow-up Visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
Drug: Leuprolide Acetate 3 Month Depot
Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
Drug: Leuprolide Acetate 3 Month Depot
Also known as: ABT-818, Lupron, Leuprorelin acetate
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \< 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.
Time frame: Day 1, Months 6, 12, 24, and 36
Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)
The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.
Time frame: Day 1, Months 3, 6, 9, 12, and 24
Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)
The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.
Time frame: Months 6, 9, 12, 24, 30, and 36
Percentage of Male Participants With Suppression of Basal Testosterone
The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone \< 30 ng/dL. Final visit is the participant's last visit closest to Month 36.
Time frame: Day 1, Months 3, 6, 9, 12, 24, 30, and 36
Mean Peak-stimulated Luteinizing Hormone Concentration by Visit
Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.
Time frame: Baseline of the lead-in study L-CP07-167, Day 1, Months 6, 12, 24, and 36
Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)
The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.
Time frame: Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36
Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)
The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.
Time frame: Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36
Change From Baseline in Growth Rate
Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.
Time frame: Baseline (the 1 year prior to the start of treatment in the lead-in study), and Day 1, Months 6, 12, 18, 24, 30, and 36
Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age
Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula: (BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).
Time frame: Baseline (of the lead-in study L-CP07-167), and Day 1, Months 12, 24, and 36
Participants who successfully completed and showed maintenance of luteinizing hormone suppression through the 6-month treatment period of the lead-in study L-CP07-167 (NCT00635817) received the same treatment in this study that they were previously assigned in the lead-in study.
| Milestone | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Started | 34 | 38 |
| Completed | 11 | 13 |
| Not completed | 23 | 25 |
| Withdrew: Ready to enter puberty based on age | 13 | 15 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Personal reasons | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Not adequately suppressed on therapy | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Therapeutic failure | 1 | 1 |
| Milestone | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Started | 28 | 26 |
| Completed | 28 | 25 |
| Not completed | 0 | 1 |
| Withdrew: No longer needed treatment | 0 | 1 |
Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \< 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N= 32, 37] | 96.9 (83.78 to 99.92) | 100.0 (90.51 to 100.00) |
| Month 6 [N=32, 36] | 93.8 (79.19 to 99.23) | 100.0 (90.26 to 100.00) |
| Month 12 [N=31, 32] | 90.3 (74.25 to 97.96) | 96.9 (83.78 to 99.92) |
| Month 24 [N=16, 18] | 87.5 (64.65 to 98.45) | 100.0 (81.47 to 100.00) |
| Month 36 [N=9, 11] | 77.8 (39.99 to 97.19) | 100.0 (71.51 to 100.00) |
| Final Visit [N=33, 36] | 93.9 (79.77 to 99.26) | 100.0 (90.26 to 100.00) |
The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N=28, 30] | 96.4 (81.65 to 99.91) | 100.0 (88.43 to 100.00) |
| Month 3 [N=29, 33] | 100.0 (88.06 to 100.00) | 100.0 (89.42 to 100.00) |
| Month 6 [N=26, 25] | 100.0 (86.77 to 100.00) | 100.0 (86.28 to 100.00) |
| Month 9 [N=18, 18] | 100.0 (81.47 to 100.00) | 100.0 (81.47 to 100.00) |
| Month 12 [N=10, 12] | 100.0 (69.15 to 100.00) | 100.0 (73.54 to 100.00) |
| Month 24 [N=1, 0] | 100.0 (2.50 to 100.00) | NA (NA to NA) |
| Final Visit [N=31, 33] | 100.0 (88.78 to 100.00) | 100.0 (89.42 to 100.00) |
The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol \< 20 pg/mL. The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Month 6 [N=4, 6] | 100.0 (39.76 to 100.00) | 83.3 (35.88 to 99.58) |
| Month 9 [N=13, 10] | 61.5 (31.58 to 86.14) | 40.0 (12.16 to 73.76) |
| Month 12 [N=20, 15] | 45.0 (23.06 to 68.47) | 60.0 (32.29 to 83.66) |
| Month 24 [N=14, 15] | 50.0 (23.04 to 76.96) | 53.3 (26.59 to 78.73) |
| Month 30 [N=9, 15] | 33.3 (7.49 to 70.07) | 26.7 (7.79 to 55.10) |
| Month 36 [N=7, 11] | 28.6 (3.67 to 70.96) | 36.4 (10.93 to 69.21) |
| Final Visit [N=24, 26] | 29.2 (12.62 to 51.09) | 30.8 (14.33 to 51.79) |
The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone \< 30 ng/dL. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N= 2, 5] | 100.0 (15.81 to 100.00) | 100.0 (47.82 to 100.00) |
| Month 3 [N=2, 5] | 100.0 (15.81 to 100.00) | 100.0 (47.82 to 100.00) |
| Month 6 [N=2, 5] | 100.0 (15.81 to 100.00) | 80.0 (28.36 to 99.49) |
| Month 9 [N=2, 5] | 100.0 (15.81 to 100.00) | 80.0 (28.36 to 99.49) |
| Month 12 [N=1, 5] | 100.0 (2.50 to 100.00) | 100.0 (47.82 to 100.00) |
| Month 24 [N=1, 3] | 100.0 (2.50 to 100.00) | 66.7 (9.43 to 99.16) |
| Month 30 [N=0, 1] | NA (NA to NA) | 100.0 (2.50 to 100.00) |
| Month 36 [N=0, 1] | NA (NA to NA) | 100.0 (2.50 to 100.00) |
| Final Visit [N=2, 5] | 100.0 (15.81 to 100.00) | 100.0 (47.82 to 100.00) |
Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.
| mIU/mL | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Baseline [N=33, 38] | 21.89 ± 38.46 | 10.16 ± 12.66 |
| Day 1 [N=32, 37] | 2.00 ± 1.03 | 1.49 ± 0.86 |
| Month 6 [N=32, 36] | 2.22 ± 1.16 | 1.62 ± 0.82 |
| Month 12 [N=31, 32] | 2.24 ± 1.20 | 1.58 ± 1.02 |
| Month 24 [N=14, 18] | 1.67 ± 0.97 | 0.88 ± 0.58 |
| Month 36 [N=7, 11] | 1.51 ± 0.85 | 0.91 ± 0.49 |
| Final Visit [N=33, 36] | 1.81 ± 1.13 | 1.15 ± 0.74 |
The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N= 31, 31] | 90.3 (74.2 to 98.0) | 83.9 (66.3 to 94.5) |
| Month 3 [N=29, 31] | 86.2 (68.3 to 96.1) | 87.1 (70.2 to 96.4) |
| Month 6 [N=31, 30] | 90.3 (74.2 to 98.0) | 80.0 (61.4 to 92.3) |
| Month 9 [N=31, 28] | 87.1 (70.2 to 96.4) | 75.0 (55.1 to 89.3) |
| Month 12 [N=28, 26] | 85.7 (67.3 to 96.0) | 80.8 (60.6 to 93.4) |
| Month 18 [N=17, 20] | 82.4 (56.6 to 96.2) | 75.0 (50.9 to 91.3) |
| Month 24 [N=14, 16] | 78.6 (49.2 to 95.3) | 75.0 (47.6 to 92.7) |
| Month 30 [N=10, 16] | 90.0 (55.5 to 99.7) | 68.8 (41.3 to 89.0) |
| Month 36 [N=8, 12] | 87.5 (47.3 to 99.7) | 66.7 (34.9 to 90.1) |
| Final Visit [N=31, 31] | 83.9 (66.3 to 94.5) | 71.0 (52.0 to 85.8) |
The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.
| percentage of participants | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N= 2, 5] | 50.0 (1.3 to 98.7) | 40.0 (5.3 to 85.3) |
| Month 3 [N=2, 5] | 50.0 (1.3 to 98.7) | 60.0 (14.7 to 94.7) |
| Month 6 [N=2, 5] | 50.0 (1.3 to 98.7) | 60.0 (14.7 to 94.7) |
| Month 9 [N=2, 5] | 50.0 (1.3 to 98.7) | 40.0 (5.3 to 85.3) |
| Month 12 [N=1, 5] | 100.0 (2.5 to 100.0) | 60.0 (14.7 to 94.7) |
| Month 18 [N=1, 3] | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) |
| Month 24 [N=1, 3] | 100.0 (2.5 to 100.0) | 33.3 (0.8 to 90.6) |
| Month 30 [N=1, 1] | 100.0 (2.5 to 100.0) | 100.0 (2.5 to 100.0) |
| Month 36 [N=0, 1] | NA (NA to NA) | 100.0 (2.5 to 100.0) |
| Final Visit [N=2, 5] | 50.0 (1.3 to 98.7) | 20.0 (0.5 to 71.6) |
Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.
| cm/year | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Baseline [N=32, 38] | 7.2 ± 3.96 | 7.53 ± 2.81 |
| Change from Baseline at Day 1 [N=32, 38] | -1.67 ± 3.90 | -1.65 ± 3.43 |
| Change from Baseline at Month 6 [N=32, 37] | -1.66 ± 3.78 | -2.04 ± 2.95 |
| Change from Baseline at Month 12 [N=28, 32] | -1.99 ± 3.90 | -2.28 ± 2.88 |
| Change from Baseline at Month 18 [N=18, 23] | -2.21 ± 4.29 | -2.06 ± 2.40 |
| Change from Baseline at Month 24 [N=15, 19] | -2.36 ± 4.85 | -1.59 ± 2.20 |
| Change from Baseline at Month 30 [N=11, 17] | -1.86 ± 5.45 | -2.13 ± 2.33 |
| Change from Baseline at Month 36 [N=8, 13] | -2.64 ± 5.93 | -2.19 ± 2.41 |
| Change from Baseline at Final Visit [N=32, 38] | -2.27 ± 3.78 | -2.64 ± 2.65 |
Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula: (BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).
| ratio | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| Day 1 [N=32, 37] | 0.51 ± 0.56 | 1.02 ± 1.27 |
| Month 12 [N=32, 32] | 0.52 ± 0.33 | 0.62 ± 0.37 |
| Month 24 [N=14, 17] | 0.53 ± 0.30 | 0.72 ± 0.34 |
| Month 36 [N=5, 11] | 0.43 ± 0.15 | 0.64 ± 0.30 |
| Final Visit [N=33, 32] | 0.48 ± 0.28 | 0.56 ± 0.30 |
Collected over 37 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate 3M Depot 11.25 mg | — | 1/34 (2.9%) | 31/34 (91.2%) |
| Leuprolide Acetate 3M Depot 30 mg | — | 0/38 (0%) | 31/38 (81.6%) |
| Event | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| INTRACRANIAL PRESSURE INCREASEDNervous system disorders | 1/34 | 0/38 |
| Event | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg |
|---|---|---|
| INJECTION SITE PAINGeneral disorders | 10/34 | 9/38 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/34 | 5/38 |
| COUGHRespiratory, thoracic and mediastinal disorders | 4/34 | 9/38 |
| PYREXIAGeneral disorders | 6/34 | 5/38 |
| HEADACHENervous system disorders | 5/34 | 6/38 |
| PHARYNGITIS STREPTOCOCCALInfections and infestations | 5/34 | 4/38 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 4/34 | 5/38 |
| NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders | 3/34 | 5/38 |
| GASTROENTERITISInfections and infestations | 4/34 | 4/38 |
| VOMITINGGastrointestinal disorders | 0/34 | 4/38 |
Participants who received at least 1 dose of study drug in this extension study.
| Age, Continuous(years) | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg | Total |
|---|---|---|---|
| Mean | 8.50 ± 1.71 | 8.45 ± 1.52 | 8.47 ± 1.60 |
| Sex: Female, Male(Participants) | Leuprolide Acetate 3M Depot 11.25 mg | Leuprolide Acetate 3M Depot 30 mg | Total |
|---|---|---|---|
| Female | 32 | 33 | 65 |
| Male | 2 | 5 | 7 |
The record gives a start of Dec 2008, a primary completion of Oct 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide
AbbVie (prior sponsor, Abbott) →